Stella Pharma Corp. Hits Day Low at JPY 558 Amid Price Pressure

Stella Pharma Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced significant volatility on April 22, 2026, with its stock price declining by 9.74%. The stock reached an intraday low of JPY 558.00, reflecting ongoing challenges within the company. Over the past week, Stella Pharma's performance has been notably poor, with a decline of 13.08%, contrasting sharply with the Japan Nikkei 225, which gained 2.5% during the same period. The company's one-month performance also shows a decrease of 6.61%, while its year-to-date performance remains strong at 178.33%, significantly outperforming the Nikkei 225's 18.37%. Despite a remarkable 80.51% increase over the past year, the company faces underlying issues, including a negative EBITDA of Rs. -55.52 crore and a low return on equity of -6.21%. The operating profit has seen a drastic annual decline of 234.76% over the last five years, indicating potential long-term growth concerns. As Stella Pharma navigates these challenges, its market position remains under scrutiny.